A phase I, open-label, randomized, crossover study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in a modified release formulation (MR2) and compare the bioavailability between MR2 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Prostate cancer; Systemic mastocytosis
- Focus Pharmacokinetics
- Sponsors Novartis
- 25 Jan 2007 New trial record.